AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Camurus AB
Video analysis: CAMRF
All videosNo video analysis for this stock yet. Request one from our team.
News: CAMRF
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA
PDUFA target action date set to 18 December 2026 LUND, Sweden, July 17, 2026 /PRNewswire/ -- Camurus (NASDAQ STO: CAMX) today announced that the US Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application (NDA) for CAM2029, octreotide extended-release injection, for the treatment of patients with acromegaly. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of 18 December 2026.
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
Camurus AB (publ) (CAMRF) Q2 2026 Earnings Call Transcript
Similar companies
-
Laboratorios Farmaceuticos Rovi, S.A.
LABFF
·
Other OTC
Compare
-
Santen Pharmaceutical Co., Ltd.
SNPHF
·
Other OTC
Compare
-
Genscript Biotech Corporation
GNNSF
·
Other OTC
Compare
-
ALK-Abelló A/S
AKBLF
·
Other OTC
Compare
-
Ambu A/S
AMBBY
·
Other OTC
Compare
-
InnoCare Pharma Limited
INCPF
·
Other OTC
Compare